Corrigendum

Corrigendum to: Serum progastrin-releasing peptide in pneumonia, chronic obstructive pulmonary disease and early-stage primary lung cancers

Gramos Begolli¹, Maja Lukić^{2,3}, Lada Rumora⁴, Lorna Čorak⁵, Andrea Vukić Dugac^{5,6}, Marko Jakopović^{5,6}, Miroslav Samaržija^{5,6}, Ilijan Tomaš^{3,7}, Jelena Knežević^{8,9}, Željko Debeljak*^{2,3}

Highlights

- In pneumonia and chronic obstructive pulmonary disease (COPD), median pro-gastrin-releasing peptide (proGRP) > 50 ng/L was measured
- Median proGRP < 40 ng/L was measured in the early-stage lung adenocarcinoma and squamous cell carcinoma
- Pneumonia and COPD patients may have higher proGRP cut-offs compared to small-cell lung cancer

This is a correction of Biochem Med (Zagreb). 2025;35:010702. DOI: https://doi.org/10.11613/BM.2025.010702

Since the publication of the article, the authors have noticed an error in the Highlights section. The correct Highlights are presented above. We apologize to the authors for any inconvenience caused to the readers.

¹Clinic of Medical Biochemistry, University Clinical Center of Kosovo, Pristina, Kosovo

²Clinical Institute of Laboratory Diagnostics, University Hospital Centre Osijek, Osijek, Croatia

³Faculty of Medicine, JJ Strossmayer University of Osijek, Osijek, Croatia

⁴Department of Medical Biochemistry and Hematology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia

⁵University Hospital Center Zagreb, Zagreb, Croatia

⁶School of Medicine, University of Zagreb, Zagreb, Croatia

⁷Oncology Department, University Hospital Centre Osijek, Osijek, Croatia

⁸Laboratory for Advanced Genomics, Ruđer Bošković Institute, Zagreb, Croatia

⁹Faculty for Dental Medicine and Health, JJ Strossmayer University of Osijek, Osijek, Croatia

^{*}Corresponding author: zeljko.debeljak@gmail.com